Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3187)	1/2/2014 5:34:04 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ERB, the old IVAX Diagnostics, that was bought by a German company, but still has its headquarters at Miami Lakes, was up a nice 42.86% on a volume around 12x its ADV. <g> The stock has had some help from a couple of recent articles on SA and its presentation on late Nov in Germany. ERB said at that time that it was particularly excited about the launching of two new high tech product offerings – the Laura XL and Hb–Vario. The Laura XL is a fully automated Urinalysis and sedimentation processor with the capability to automate Urine strip reading as well as performing sedimentation cell analysis for abnormal samples. The estimated IVD Urinalysis market is approximately $600 Million USD per year. ERBA will also be showcasing the Hb-Vario, an automated HPLC system that is capable of measuring both HbA1c/ and A2 for the monitoring of diabetes. Diabetes continues to be one of the major challenges worldwide to the healthcare industry. The benefits of monitoring A1c values to better manage diabetes is well documented in numerous studies. The measurement control of A1c values is key to reducing co-morbidity complications within this population. Glycated hemoglobin (HbA1c) testing is poised to emerge as a popular technology with outpatient clinics and other small hospital-based laboratories according to a Global Industry Analyst report. The same report also forecasts that the global market for Diabetes Diagnostics is estimated to reach US$26 billion by the year 2015. Bio-Rad and Tosoh are the market leaders in this segment. Diabetes testing is a focus area for growth for ERBA. With the launching of these two exciting products, ERBA expects to further grow its existing global market share in these two segments. ERBA is now strongly focused on new product developments and looks forward to the ever increasing product portfolio to serve the health care providers and patients worldwide. It seems that with some help, the stock could get to the $4 level <g> bigcharts.marketwatch.com Bernard